Praxis Precision Medicines Inc (PRAX) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Praxis Precision Medicines Inc (US:PRAX), trading at 307.75. In 2024, Praxis Precision Medicines Inc generated $8.55 Million in revenue and -$131.76 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Praxis Precision Medicines Inc is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: 307.75
- Recent Revenue (2024): $8.55 Million
- Free Cash Flow (2024): -$131.76 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.